Document is current
Any future updates will be listed below
-
Authors
Gerards, Nienke R. https://orcid.org/0009-0002-7288-7416
Wiegers, Sanne E. https://orcid.org/0000-0003-3698-8121
Bes, Anne L.
Eertink, Jakoba J. https://orcid.org/0000-0002-6094-0016
Lugtenburg, Pieternella J. https://orcid.org/0000-0002-6735-8651
Zijlstra, Josée M. https://orcid.org/0000-0003-1074-5922
Boellaard, Ronald https://orcid.org/0000-0002-0313-5686
Zwezerijnen, Gerben J.C. https://orcid.org/0000-0002-9571-9362
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (2018-11648)
- License Information
-
More Information
Article History
Received: 16 April 2025
Accepted: 1 August 2025
First Online: 18 August 2025
Declarations
:
: The HOVON-84 study was approved by the institutional review board of the Erasmus MC (2007-055) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later versions.
: Written informed consent was obtained from all individual participants included in the HOVON-84 study.
: Pieternella Lugtenburg received financial support for clinical trials from Takeda and Roche. Josée Zijlstra received financial support for clinical trials from Roche, Gilead, and Takeda. Ronald Boellaard is scientific advisor of the EARL PET/CT accreditation programme. No other potential conflict of interest relevant to this article was reported.
